Hong Kong stocks rallied significantly, led by technology stocks.$恒生指數(800000.HK)$once hiked 473 points to a 5-month high of 17,758 in the afternoon, and closed lifting 366 points or 2.1% at 17,651.$國企指數(800100.HK)$escalated 149 points or 2.4% to close at 6,269.$恒生科技指數(800700.HK)$surged 163 points or 4.6% to close at 3,718. Total turnover for the whole day was $157.242 billion, the highest in th...
The Nasdaq fell on its first trading day of 2024, with$蘋果(AAPL.US)$, which was downgraded to "underweight" by Barclays with TP down to US$160, continuing to drop 3.6%. In addition,$納斯達克中國金龍指數(.HXC.US)$, which reflects the performance of Chinese ADRs, lost 3.5%. $恒生科技指數(800700.HK)$busted below the 20 and 10MAs to bottom at 3,627, and last at 3,630, down 2.3%.$恒生指數(800000.HK)$also miss...
Acquisition Details: - ALI HEALTH is acquiring the entire issued share capital of AJK Technology from its controlling shareholder$阿里巴巴-SW(09988.HK)$. - Consideration: HK$13.512 billion. - Consideration includes issuing 2.558 billion shares at HK$4.50 per share and paying USD Equivalent of HK$2 billion in cash. Businesses of AJK Technology: - Exclusive Marketing Materials...
$阿里健康(00241.HK)$under$阿里巴巴(BABA.US)$announced that Shen Difan, executive Director of the Company, was appointed as the chief executive officer of the Company, with effect from the close of business yesterday (28th). With effect from the same date, Zhu Shunyan tendered his resignation as the Chief Executive Officer, and will remain as an executive Director, the chairman of the Board and the chairman of the nomination committee of the Company, for the pur...
1. Record Results: China’s leading electric vehicle manufacturer posted yet another set of record results. BYD Company announced 3Q results that defied slowing industry growth in an increasingly saturated market. Revenues for the period jumped 38.5% to RMB 162.2 billion, while net profits grew 82.2% to RMB 10.41 billion. That was about mid-point of the the company’s early estimates of a 67% to 102% growth in profits announced on Oc...
阿里健康股票討論區
HSI Closes Rallying 366 pts, as Techs Rise; SENSETIME Skyrockets 43%
HSTECH 2.3% Lower; TENCENT/ NTES Sturdy;JD HEALTH Dive 5%-6.5%
$恒生科技指數(800700.HK)$ busted below the 20 and 10MAs to bottom at 3,627, and last at 3,630, down 2.3%. $恒生指數(800000.HK)$ also miss...
HSI Closes at 17,042, Up 49 pts; TENCENT Up over 3%; NEW ORIENTAL Hit New Highs; Market Turnover Rises
Active Heavyweights:
$騰訊控股(00700.HK)$ closed at $327, up 3.2%
$美團-W(03690.HK)$ closed at $90.6, up 0.2%
$阿里巴巴-SW(09988.HK)$ closed at $72.75, up...
ALI HEALTH Issues New Shrs to Buy Marketing Right for Healthcare Categories from Parent Co., Involving $13.5B
- ALI HEALTH is acquiring the entire issued share capital of AJK Technology from its controlling shareholder $阿里巴巴-SW(09988.HK)$ .
- Consideration: HK$13.512 billion.
- Consideration includes issuing 2.558 billion shares at HK$4.50 per share and paying USD Equivalent of HK$2 billion in cash.
Businesses of AJK Technology:
- Exclusive Marketing Materials...
ALI HEALTH Changes CEO
With effect from the same date, Zhu Shunyan tendered his resignation as the Chief Executive Officer, and will remain as an executive Director, the chairman of the Board and the chairman of the nomination committee of the Company, for the pur...
Here's what happened in China's markets last trade day (10/31):
BYD Company announced 3Q results that defied slowing industry growth in an increasingly saturated market. Revenues for the period jumped 38.5% to RMB 162.2 billion, while net profits grew 82.2% to RMB 10.41 billion. That was about mid-point of the the company’s early estimates of a 67% to 102% growth in profits announced on Oc...
However, $阿里巴巴-SW(09988.HK)$ sank 1.3% to $81.8. $商湯-W(00020.HK)$ ebbed back 2.1% to $1.4. $阿里健康(00241.HK)$ dropped 1.9% to $4.71.
HSI Up 272 pts; HSTI Up 58 pts; SENSETIME-W Up over 6%
HSI & HSCEI Constituents on Move:
$商湯-W(00020.HK)$ closed at $1.43, up 6.7%
$阿里健康(00241.HK)$ closed at $4.8, up 4.1%
$龍湖集團(00960.HK)$ closed at $13.42, up 3.4%
$中國生物製藥(01177.HK)$ clos...
暫無評論